The Centauri Colony
Dr. Kataga Nordman
A xenobiologist working on a cure for the Crimson Plague
Str 10, Dex 9, Con 12, Int 16, Wis 15, Cha 11.
Medium Humanoid (Human) Female
HD 8d6+8;HP 35
Spd 30 ft.
AC 12, touch 12, flat-footed 12 (+3 class, -1 Dex)
Atk +3 melee (1d3 nonlethal, punch)
Full +3 melee (1d3 nonlethal, punch)
Saves Fort +3, Ref +1, Will +8; AP 0; Rep +3
PL Familiarity: 6
Occupation: Academic Researcher
Skills: Barter +5, Computer Use +14, Decipher
Script +16, Drive +3, Investigate +14,
Knowledge (Current Events) +11, Knowledge
(History) +16, Knowledge (Technology) +16,
Knowledge (Biology) +16,
Profession (Scholar) +13, Read/Write Language
(English, French, Indian, Mandarin Chinese,
Phaethian Pidgin, Galactic Basic), Research +16, Search +14,
Speak Language (English, French, Indian,
Mandarin Chinese, Paethian Pidgin, Galactic Basic).
Feats: Educated x2, Iron Will, Simple Weapons
Possessions: Info-comp, clothes, pencils,
pens, paper, glasses
Dr. Nordman is a Phaethian virologist and director of the Regulation of Retroviral Infections Division (RRID) of Tarsis Major at the Pasteur Institute in Tarsis, Tarsis Major on Phaethon. Born in Paris, France, Barré-Sinoussi performed some of the fundamental work in the identification of the Crimson Plague virus (CPV). She was awarded the Phaethon Nobel Prize in Xenobiology or Medicine, together with her former mentor, Jean Montagnier, for their discovery and classification of CPV.
She received her PhD in 3475 and interned at the Tarsis Major National Institute of Health before joining the Pasteur Institute. Nordman’s research quickly turned to a particular group of viruses, the retroviruses. Her knowledge in this field led her to discover CPV in 3483. This discovery revealed an urgent need for diagnostic tests to aid in controlling the spread of the disease. Nordman started her own laboratory at the Pasteur Institute in 3485 after the death of her mentor Jean Montagnier.
Among Nordman’s many recent research contributions are studies of various aspects of the adaptive immune response to viral infection, the role of innate immune defences of the host in controlling CPV, factors involved in mother-to-child transmission of CPV, and characteristics that allow a small percentage of CPV-positive individuals, known as Controllers, to limit CPV replication by administering antiretroviral drugs. She has authored or co-authored over 240 scientific publications, has participated in over 250 global conferences, and has trained many young researchers.
She is currently behind the Net on Phaethon researching a potential cure for CPV.